Measure commercial capability across organisations, programmes and markets.

By applying one commercial methodology to every participating organisation, so the results are comparable rather than a collection of separate opinions. Each participant is assessed across the ten Commercial Transformation Index domains, and the individual readings aggregate into a capability profile for the programme population. Because the method is fixed in advance, a later reassessment measures change rather than measuring a different question.

Where commercial capability sits across a defined population at a point in time: the distribution of Commercial Maturity Bands, the domains where capability is consistently weaker, and the dependencies that are limiting value elsewhere in the system. A baseline is the measurement every later reading is compared against, which is why it is taken before intervention rather than alongside it.

That is the condition that makes cohort measurement mean anything. Every participant is assessed under the same methodology version, the same domain structure and the same evidence rules, and the evidence class behind each reading is recorded. Results produced under different assessment routes are not interchangeable, so a cohort is measured under one route and the route is stated with the findings.

A constraint that appears in one organisation is a finding about that organisation. The same constraint appearing across a population is a finding about the population, and it is usually the one worth funding. Aggregating comparable assessments shows which domains are weak across the group, which dependencies repeatedly fail, and which segments of the cohort carry which constraint.

Yes, and that is the most common reason a programme commissions measurement. Segmenting a cohort by capability, sector, size or region shows which participants need which kind of support, and in what order. The evidence describes commercial condition; deciding what support to fund and who delivers it remains the programme owner’s decision.

Yes. Reassessment under the same methodology version produces a change view: movement between Commercial Maturity Bands, domains where capability improved, and constraints that persisted. Comparison is only valid where the assessment route and the methodology version match, so both are recorded with every reading and stated with any movement figure.

Assessment results at organisation level for the recipients each participant has authorised, and at cohort level a commercial capability profile, the Commercial Maturity Band distribution, recurring constraints, domain-level patterns, segmentation across suitable cohort dimensions, intervention priorities, a reassessment view where the programme repeats, and the provenance and evidence-class context behind all of it. Exactly what a given programme receives is set by its scope and the consents in place.

The methodology is independent of who implements support. CTI measures commercial capability, identifies where the constraints sit and provides the evidence for targeting; the intervention can be delivered by the programme itself, by its existing suppliers, or by anybody it appoints. Keeping measurement separate from delivery is what allows the evidence to be used to choose an intervention rather than to justify one.

Aggregate findings can be published where the programme agrees and the evidence supports it. Publication describes the population rather than any named participant: a figure appears only where the cohort behind it clears the cohort suppression rules, and it carries its population, its period and what it cannot establish. Individual organisation results are private to that organisation and its authorised recipients.

The methodology, the domain model, the evidence classes and the publication rules are published, so a research team can examine and apply the framework without commissioning anything. Collaboration is normally built around a defined population and a defined commercial research question: cohort studies, sector or regional capability, longitudinal measurement, or CTI analysis of an external public source published as source-specific evidence attributed to that source.

Raw participant data, unrestricted access to the evidence base, and the proprietary part of the method. The criterion architecture, the scoring anchors, the weighting and aggregation and the analytical logic behind a finding stay proprietary, because publishing the arithmetic would let a result be engineered rather than earned. Collaboration also confers no academic validation of the framework and no automatic co-authorship.

A membership is already a defined population, which is what makes cohort measurement possible. Assessing members under one method produces a capability baseline for the membership, segmentation by sector, size or region, the constraints that recur among members, and evidence for designing member services against what members actually need rather than against what they report wanting.

Defining the population first, then applying the same commercial methodology across it so the findings describe that sector or that geography rather than a convenience sample. Findings are published with the cohort, the period, the evidence classes behind them and their limitations. Sector and regional research follows the same suppression rules as any other CTI publication.

Financial performance describes what has happened. A commercial-system assessment examines whether the system producing it is structured to keep producing it, across all ten domains and the dependencies between them, with the evidence behind each finding stated. Applied repeatedly it gives a comparable view across a portfolio and a baseline to remeasure against after investment. It is not a credit score, a rating, a forecast or an investment recommendation.

Yes. The common model is that CTI measures and diagnoses, and the partner supports or delivers the change the organisation decides to make. Advisors frequently use an independent reading precisely because a diagnosis produced by the party proposing the work is harder for a client to act on. There is no public partner certification scheme.

No, and the safeguards are published rather than promised. The method is public, the class of evidence is recorded against every reading, and publication and suppression thresholds are fixed before a result is known. A reading that the evidence does not support cannot quietly become one that it does, whoever stands to deliver the work that follows.

Evidence gathered in an assessment belongs to the organisation that was assessed and is private by default. Research use is a separate recorded consent rather than a condition of taking part. Aggregate outputs describe the cohort, appear only where the population behind them clears the suppression rules, and carry their evidence classes and limitations with them. How information is handled is set out in the privacy notice.

Interest is registered as an expression of interest rather than against a posted vacancy, and it is held against the kind of work it fits: research, analysis, commercial systems, programme work, evidence and data, or publishing. Contributor and collaborator interest from people already working in commercial research is welcome on the same basis.